MYOLYN has received 510(k) clearance from the US Food and Drug Administration on a new, second version of its flagship product, the MyoCycle. With 4 new models, the MyoCycle brings functional electrical stimulation (FES) cycling therapy to at-home and clinical-setting users. The new models—Home, Home Plus, Pro, and Pro Plus—offer advanced technologies to better meet patient needs, such as additional stimulation channels, new walking and cycling modes, additional muscle group targeting options for core and lower leg muscles, new FDA-cleared benefit of muscle re-education, real-time performance feedback, and more adjustable stimulation parameters. With new muscle group targeting of the core and lower legs, in addition to the thighs and glutes, the MyoCycle can benefit those who face a variety of medical conditions resulting in lower-body paralysis or muscle weakness, including spinal cord injuries, stroke, multiple sclerosis, brain injury, Parkinson’s disease, cerebral palsy, foot drop, and general orthopedic rehabilitation.
MYOLYN
352/306-5873
